CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...
Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...
Mayo Clinic on MSN
COVID-19 vaccines: Get the facts
The 2025-2026 COVID-19 vaccines available in the United States include Moderna, Pfizer-BioNTech and Novavax. The vaccines are all approved for people age 65 and older. Each vaccine also is approved ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.
Historically, RSV has been associated with infants, but they are not the only group that can be affected by serious RSV ...
New research shows Moderna and Pfizer’s mRNA vaccines may prime the immune system to attack cancer—even better than some ...
Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in ...
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...
Investor's Business Daily on MSN
Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust
Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback